Infantile ColicNCT03877458
Combined Probiotics is More Effective in the Treatment of Infantile Colic
A study testing L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088 and L. reuteri GL-104 in people with Infantile Colic, run by China Medical University Hospital at 1 site in Taiwan.
Trial summary
All participants are randomized into 1 of 3 treatment arms, the mixture L acidophilus, B longum and B. bifidum group, Lactobacillus reuteri or placebo group. Primary outcome is defined as a reduction in the duration of average crying and fussing times, from baseline (day 0) to age 6 months, to <3 hours per day. Read more about this study
- Who is it for?
- Ages 3 weeks to 3 months
- Conditions the study is for
- Infantile Colic
- What is being tested?
- L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088 and L. reuteri GL-104
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 99 participants
- Where
- 1 siteTaiwan
- Study dates
- 16 Feb 2017to 31 Dec 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 weeks to 3 months
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Diagnosis of infantile colic (ie, crying or fussy/gassy episodes ≥3 hours/day for ≥3 days/7 days, as defined by a modified definition of Wessel criteria) at study commencement.
- Age 3 weeks to 3 months at study commencement.
- Infants are born in full term (greater than 37 weeks) and the birth weight more than 2500 grams.
Who cannot join
- A major medical problem or acute illness, including gastroesophageal reflux, as determined by a pediatrician.
- History of antibiotic treatment before or during the study.
- History of probiotic supplementation.
- History of any allergies to any of the ingredients in the probiotic mixture of L. acidophilus, B. longum and B. bifidum or placebo.
- Concurrent participation in another clinical trial.
Trial locations and contacts
1 site in 1 country.
About this study
All participants are randomized into 1 of 3 treatment arms, the mixture L acidophilus, B longum and B. bifidum group, Lactobacillus reuteri or placebo group.
Primary outcome is defined as a reduction in the duration of average crying and fussing times, from baseline (day 0) to age 6 months, to <3 hours per day. Secondary outcome are the number of participants who respond to treatment on days 7, 14, 21, 28 and each month till age 6 months.
Read the detailed description
Infantile colic or excessive infant crying with no medical cause is a burdensome condition. Although crying is often considered "normal behavior," 5%-40% of infants cry inconsolably and excessively, accompanied by bouts of fussiness and gas passing.
The etiology of infantile colic remains unclear; various theories have been proposed, however, recent studies have implicated a potential role of the intestinal microbiome ,colicky infants presents lower amounts of Bifidobacteria and Lactobacilli. Several randomized clinical trials (RCT) have been conducted to examine the effectiveness of Lactobacillus reuteri DSM17938 vs placebo in the treatment of infantile colic. However, there is no trial adopt probiotics contained Bifidobacteria and Lactobacilli to treat infantile colic. In view of the above evidences, the investigators thus hypothesis that probiotics contained Bifidobacteria and Lactobacilli will more effect to increase the diversity of intestinal microbiome and alleviate infantile colic. The objective of this study is to evaluate the efficacy of combine probiotics (L. acidophilus, B. longus and B. bifidus) compare to Lactobacillus reuteri in the treatment infantile colic. Fecal calprotectin levels and microbial community in colic infants before and after probiotics will be evaluated to explore the mechanism of effectiveness of probiotics.
This, double-blind RCT will be carried out from December 2016 to November 2018 at Children's hospital of China Medical university. Eligible infants are included in the study after written informed consent is obtained from a parent/guardian. Study participants will meet the following inclusion criteria: (1) diagnosis of infantile colic (ie, crying or fussy/gassy episodes ≥3 hours/day for ≥3 days/7 days, as defined by a modified definition of Wessel criteria) at study commencement; (2) age 3 weeks to 5 months at study commencement (although infantile colic typically manifests between age 2 weeks and 3-4 months, to capture infants with delayed onset of colic, infants with colic up to 6 months were eligible); (3) exclusively breastfed; (4) term delivery (≥37 weeks gestation); and (5) healthy infants with birth weight ≥2500 g. Exclusion criteria included: (1) a major medical problem or acute illness, including gastroesophageal reflux, as determined by a pediatrician; (2) history of antibiotic treatment before or during the study; (3) history of probiotic supplementation; (4) history of any allergies to any of the ingredients in the probiotic mixture of acidophilus, B longus and B. bifidus or placebo (sunflower oil, medium-chain triglyceride oil, and silicon dioxide); and (5) concurrent participation in another clinical trial.
Primary outcome is defined as a reduction in the duration of average crying and fussing times, from baseline (day 0) to age 6 months, to <3 hours per day. Secondary outcome are the number of participants who respond to treatment on days 7, 14, 21, 28 and each month till age 6months.
All participants are randomized into 1 of 3 treatment arms, the mixture L acidophilus, B longus and B. bifidus group, Lactobacillus reuteri or placebo group. Independent Research Support Pharmacy personnel, not participating in the study at the pharmacy of the Children Hospital prepare a computer-generated 3-treatment randomization schedule with a random block of varying size to ensure balance in the allocation of participants between treatment arms. Stool bacterial microbiota will be accessed by next generation sequence and fecal calprotectin will be measured by ELISA.
A minimum of 60 participants per study arm is needed to provide 80% power to detect an effect size of 0.5 and a detectable difference between groups in mean crying and fussing times of 50 minutes. Statistical analyses are performed using SPSS version 20 (IBM, Armonk, New York) using an intention-to-treat approach. The Student t test is used to compare mean values of continuous variables approximating a normal distribution, and the Mann-Whitney U test is used for nonnormally distributed variables. Proportions are compared using the χ2 test or Fisher exact test, as appropriate. All reported statistical tests are 2-sided.
- Conditions
- Infantile Colic
- Being tested
- L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088, L. reuteri GL-104, Placebo
- Keywords
- Infantile Colic, Bifidobacteria and Lactobacilli, Intestinal Microbiome, Probiotics
- Medical subject headings
- Colic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088Other
Taking 1 mix probiotics capsule at bed time everyday for three months.
L. reuteri GL-104Other
Taking 1 probiotic capsule at bed time everyday for three months.
PlaceboOther
Taking 1 placebo capsule at bed time everyday for three months.
| Study group | Role | What they receive |
|---|---|---|
| L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088 | Experimental | Taking 1 mix probiotics capsule at bed time everyday for three months. Receives: Other: L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088 |
| L. reuteri GL-104 | Experimental | Taking 1 probiotic capsule at bed time everyday for three months. Receives: Other: L. reuteri GL-104 |
| Placebo group | Placebo comparator | Taking 1 Placebo capsule at bed time everyday for three months. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average crying and fussing times.
Change in the duration of average crying and fussing times from baseline (day 0) to age 6 months, to <3 hours per day.
Measured: 6 months.
Secondary outcomes (1)
The number of participants.
The number of participants who respond to treatment on days 7, 14, 21, 28 and each month till age 6 months.
Measured: 6 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2019
- Study start16 Feb 2017
- Primary completion11 Nov 2021
- Study completion31 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Infantile ColicStudies of the same condition, open and under way.
- More trials run by China Medical University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 99 participants (actual)
Sponsor and investigators
- Lead sponsor
- China Medical University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shu-Fen Wu, China Medical University Hospital
- Investigators
- Hung-chih Lin, Study director, China Medical University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03877458
- Sponsor's protocol ID
- CMUH105-REC1-155
- Status last verified
- Mar 2023
- First submitted
- 12 Mar 2019
- Last updated
- 22 Mar 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Combined Probiotics is More Effective in the Treatment of Infantile Colic
- ClinicalTrials.gov ID
- NCT03877458
- Acronym / sponsor ID
- CMUH105-REC1-155
- Conditions
- Infantile Colic
- Keywords
- Infantile Colic, Bifidobacteria and Lactobacilli, Intestinal Microbiome, Probiotics
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 99 participants (actual)
- Lead sponsor
- China Medical University HospitalUniversity, hospital or other
- Study start
- 16 Feb 2017 (actual)
- Primary completion
- 11 Nov 2021 (actual)
- Study completion
- 31 Dec 2022 (actual)
- First posted
- 15 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
All participants are randomized into 1 of 3 treatment arms, the mixture L acidophilus, B longum and B. bifidum group, Lactobacillus reuteri or placebo group.
Primary outcome is defined as a reduction in the duration of average crying and fussing times, from baseline (day 0) to age 6 months, to <3 hours per day. Secondary outcome are the number of participants who respond to treatment on days 7, 14, 21, 28 and each month till age 6 months.
Detailed description
Infantile colic or excessive infant crying with no medical cause is a burdensome condition. Although crying is often considered "normal behavior," 5%-40% of infants cry inconsolably and excessively, accompanied by bouts of fussiness and gas passing.
The etiology of infantile colic remains unclear; various theories have been proposed, however, recent studies have implicated a potential role of the intestinal microbiome ,colicky infants presents lower amounts of Bifidobacteria and Lactobacilli. Several randomized clinical trials (RCT) have been conducted to examine the effectiveness of Lactobacillus reuteri DSM17938 vs placebo in the treatment of infantile colic. However, there is no trial adopt probiotics contained Bifidobacteria and Lactobacilli to treat infantile colic. In view of the above evidences, the investigators thus hypothesis that probiotics contained Bifidobacteria and Lactobacilli will more effect to increase the diversity of intestinal microbiome and alleviate infantile colic. The objective of this study is to evaluate the efficacy of combine probiotics (L. acidophilus, B. longus and B. bifidus) compare to Lactobacillus reuteri in the treatment infantile colic. Fecal calprotectin levels and microbial community in colic infants before and after probiotics will be evaluated to explore the mechanism of effectiveness of probiotics.
This, double-blind RCT will be carried out from December 2016 to November 2018 at Children's hospital of China Medical university. Eligible infants are included in the study after written informed consent is obtained from a parent/guardian. Study participants will meet the following inclusion criteria: (1) diagnosis of infantile colic (ie, crying or fussy/gassy episodes ≥3 hours/day for ≥3 days/7 days, as defined by a modified definition of Wessel criteria) at study commencement; (2) age 3 weeks to 5 months at study commencement (although infantile colic typically manifests between age 2 weeks and 3-4 months, to capture infants with delayed onset of colic, infants with colic up to 6 months were eligible); (3) exclusively breastfed; (4) term delivery (≥37 weeks gestation); and (5) healthy infants with birth weight ≥2500 g. Exclusion criteria included: (1) a major medical problem or acute illness, including gastroesophageal reflux, as determined by a pediatrician; (2) history of antibiotic treatment before or during the study; (3) history of probiotic supplementation; (4) history of any allergies to any of the ingredients in the probiotic mixture of acidophilus, B longus and B. bifidus or placebo (sunflower oil, medium-chain triglyceride oil, and silicon dioxide); and (5) concurrent participation in another clinical trial.
Primary outcome is defined as a reduction in the duration of average crying and fussing times, from baseline (day 0) to age 6 months, to <3 hours per day. Secondary outcome are the number of participants who respond to treatment on days 7, 14, 21, 28 and each month till age 6months.
All participants are randomized into 1 of 3 treatment arms, the mixture L acidophilus, B longus and B. bifidus group, Lactobacillus reuteri or placebo group. Independent Research Support Pharmacy personnel, not participating in the study at the pharmacy of the Children Hospital prepare a computer-generated 3-treatment randomization schedule with a random block of varying size to ensure balance in the allocation of participants between treatment arms. Stool bacterial microbiota will be accessed by next generation sequence and fecal calprotectin will be measured by ELISA.
A minimum of 60 participants per study arm is needed to provide 80% power to detect an effect size of 0.5 and a detectable difference between groups in mean crying and fussing times of 50 minutes. Statistical analyses are performed using SPSS version 20 (IBM, Armonk, New York) using an intention-to-treat approach. The Student t test is used to compare mean values of continuous variables approximating a normal distribution, and the Mann-Whitney U test is used for nonnormally distributed variables. Proportions are compared using the χ2 test or Fisher exact test, as appropriate. All reported statistical tests are 2-sided.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088 | Experimental | Other: L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088Taking 1 mix probiotics capsule at bed time everyday for three months. |
| L. reuteri GL-104 | Experimental | Other: L. reuteri GL-104Taking 1 probiotic capsule at bed time everyday for three months. |
| Placebo group | Placebo comparator | Other: PlaceboTaking 1 Placebo capsule at bed time everyday for three months. |
Who may qualify
- Ages
- 3 weeks to 3 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- Diagnosis of infantile colic (ie, crying or fussy/gassy episodes ≥3 hours/day for ≥3 days/7 days, as defined by a modified definition of Wessel criteria) at study commencement.
- Age 3 weeks to 3 months at study commencement.
- Infants are born in full term (greater than 37 weeks) and the birth weight more than 2500 grams.
Key exclusion criteria (5 listed)
- A major medical problem or acute illness, including gastroesophageal reflux, as determined by a pediatrician.
- History of antibiotic treatment before or during the study.
- History of probiotic supplementation.
- History of any allergies to any of the ingredients in the probiotic mixture of L. acidophilus, B. longum and B. bifidum or placebo.
- Concurrent participation in another clinical trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088Taking 1 mix probiotics capsule at bed time everyday for three months. | Other | L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088 |
| L. reuteri GL-104Taking 1 probiotic capsule at bed time everyday for three months. | Other | L. reuteri GL-104 |
| PlaceboTaking 1 placebo capsule at bed time everyday for three months. | Other | Placebo group |
Primary outcome
Average crying and fussing times.
Time frame: 6 months.
Change in the duration of average crying and fussing times from baseline (day 0) to age 6 months, to <3 hours per day.
1 secondary outcome
The number of participants.
Time frame: 6 months.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Mar 2023.
Related trials for Infantile Colic
RecruitingPhase 3
Comparative Efficacy of IV Dexamethasone vs. Nebulized Terbutaline for Renal Colic Pain in the ED
Renal Colic
Recruiting
The Effect of Probiotics in Infantile Colic
Infantile Colic
Active, not recruiting
Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic
Infantile Colic
Recruiting
Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)
Rectal Cancer, Colon Cancer
Active, not recruiting
RELIEF-pathway in Patients With Upper Abdominal Pain
Abdominal Pain, Gallstone; Colic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hung-chih Lin study director
China Medical University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088 and L. reuteri GL-104 in people with Infantile Colic, run by China Medical University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average crying and fussing times. (time frame: 6 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Mar 2023.